Biopharmecuticals: Approval Trends in 2006 - Thirteen biopharmaceuticals gained marketing authorization - BioPharm International

ADVERTISEMENT

Biopharmecuticals: Approval Trends in 2006
Thirteen biopharmaceuticals gained marketing authorization


BioPharm International
Volume 21, Issue 9

Clinical data supporting approval was predominantly generated by an open label, multinational randomized trial involving 463 patients. One group was administered the product while the other group received supportive care alone. Administration of Vectibix resulted in prolonged progression-free survival, from an average of 60 days to 96 days. The most common and sometimes severe negative side effects included dermatologic toxicities and adverse (sometimes severe infusion related) reactions also occurred in a minority of recipients. The product is manufactured and marketed by Amgen (Thousand Oaks, CA).

Gary Walsh, PhD, is an associate professor in the Industrial Biochemistry Program at the University of Limerick, Limerick City, Ireland, +353.61.202664,

REFERENCES

1. US Food and Drug Administration. Approvals of FDA-regulated products. Available from http://www.fda.gov/opacom/7approvl.html.

2. European Medicines Agency. EMEA annual report 2006. Available from http:// http://www.emea.europa.eu/index/indexh1.htm.

3. European Medicines Agency. EPARs for authorised medicinal products for human use. Available from http:// http://www.emea.europa.eu/htms/human/epar/eparintro.htm.

4. Walsh G. Biopharmaceuticals: approvals and approval trends in 2004. BioPharm Int. 2005;18(8):58–65.

5. Walsh, G. Biopharmaceuticals: approval trends in 2005. BioPharm Int. 2006;19(8):58–68.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Suppliers Seek to Boost Single-Use Technology
August 21, 2014
Bristol-Myers Squibb and Celgene Collaborate on Immunotherapy and Chemotherapy Combination Regimen
August 20, 2014
USP Center in Ghana Receives International Lab Accreditation
August 15, 2014
USP Awards Analytical Research
August 15, 2014
FDA Warns about Fraudulent Ebola Treatments
August 15, 2014
Author Guidelines
Source: BioPharm International,
Click here